TRPV1 and pterygium: This strategy may provide a selective approach to inhibit TRPV1 upregulation and activation, which in turn suppresses angiogenesis, fibrosis as well as inflammatory processes in different pathophysiological conditions such as dry eye disease (DED), pterygium, and conjunctivitis sicca or red eyes (16, 94, 107).